A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-25

Study Completion Date

2017-03-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is an open label, randomized, three-way crossover study to assess the effect of particle size on the PK and safety of single inhaled doses of AZD7594 in healthy subjects (males aged 18 to 55 years \[inclusive\]). The study will be performed at a single study center.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis

NCT02950805

Pulmonary/Respiratory Diseases

COMPLETED PHASE1

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa

NCT00712166

Cystic Fibrosis Lung Infection Pseudomonas Aeruginosa

COMPLETED PHASE3

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

NCT02679729

Cystic Fibrosis

COMPLETED PHASE1

A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis

NCT00769119

Bronchiectasis

COMPLETED PHASE2

Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)

NCT01855230

COPD

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will comprise:

* A Screening period of maximum 28 days.
* Three treatment periods during which subjects will be resident prior to the evening meal the 1 day before dosing with AZD7594 (Day -1) until at least 48 hours after dosing; discharged on the morning of Day 3. Subjects will then return for ambulatory visits 72, 96, 144 and 240 hours after dosing, (Day 4, Day 5, Day 7 and Day 11 respectively).
* A final Follow-up Visit within 10 days after the last administration of AZD7594. This visit will coincide with the last PK sample collection on Day 11 after the last Treatment Period.

There will be a minimum wash-out period of 21 and maximum of 28 days between each dose administration.

Subjects will attend a Screening Visit within 28 days before receiving their first dose of AZD7594, if they are found to be eligible, they return for Treatment Period 1, when they will have baseline assessments, and then will be randomized into one of the 6 treatments sequences. For each Treatment Period, the subjects will receive their investigational medicinal product (IMP) dose in the morning of Day 1, will have further assessments for 48 hours after dosing (residential period) and will return to the study center for ambulatory visits 72, 96, 144 and 240 hours after dosing, (Day 4, Day 5, Day 7 and Day 11 respectively).

Each subject will receive AZD7594 as a single inhaled dose of 440 µg (nominal dose) of each of the following treatments, administered via Dry powder inhaler (DPI):

* Treatment A: Particle size Large
* Treatment B: Particle size Medium
* Treatment C: Particle size Small Each subject will be involved in the study for up to 12 weeks (up to 4 weeks for enrollment and 8 weeks of active study and Follow-up).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma, Chronic Obstructive Pulmonary Disease (COPD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment A - AZD7594

Treatment A - AZD7594 inhalation powder Particle size Large

Group Type EXPERIMENTAL

Treatment A - AZD7594

Intervention Type DRUG

Particle size Large as a single inhaled dose of 440 µg (nominal dose), administered via DPI

Treatment B - AZD7594

Treatment B - AZD7594 inhalation powder Particle size Medium

Group Type EXPERIMENTAL

Treatment B - AZD7594

Intervention Type DRUG

Particle size Medium as a single inhaled dose of 440 µg (nominal dose), administered via DPI

Treatment C - AZD7594

Treatment C - AZD7594 inhalation powder Particle size Small

Group Type EXPERIMENTAL

Treatment C - AZD7594

Intervention Type DRUG

Particle size Small as a single inhaled dose of 440 µg (nominal dose), administered via DPI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treatment A - AZD7594

Particle size Large as a single inhaled dose of 440 µg (nominal dose), administered via DPI

Intervention Type DRUG

Treatment B - AZD7594

Particle size Medium as a single inhaled dose of 440 µg (nominal dose), administered via DPI

Intervention Type DRUG

Treatment C - AZD7594

Particle size Small as a single inhaled dose of 440 µg (nominal dose), administered via DPI

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Provision of signed and dated, written informed consent prior to any study specific procedures.
2. Healthy male subjects aged 18 to 55 years (inclusive) with suitable veins for cannulation or repeated venipuncture.
3. Have a body mass index (BMI) between 18 and 29.9 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
4. Subjects should be willing to follow reproductive restrictions to prevent pregnancy and drug exposure of a female partner and refrain from donating sperm or fathering a child from the first day of dosing until 3 months after the last dose of IMP.
5. Be able to inhale from the DPI devices according to given instructions.
6. Subjects must read, speak and understand German language.

Exclusion Criteria

1. History of any clinically significant disease or disorder which, in the opinion of the PI, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.
2. History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
3. Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.
4. Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis results, at screening and first admission to the study unit as judged by the PI.
5. Any clinically significant abnormal findings in vital signs at screening and first admission to the study unit, as judged by the PI. Abnormal vital signs, after 10 minutes supine rest, defined as any of the following: - Systolic BP (SBP) \< 90 mmHg or \> 140 mmHg - Diastolic BP (DBP) \< 50 mmHg or \> 90 mmHg - Heart rate \< 45 or \> 90 beats per minute.
6. Any clinically significant abnormalities on 12-lead ECG at screening and first admission to the study unit, as judged by the PI.
7. Any positive result on screening for serum hepatitis surface antigen or antiHBc antibody suggestive of hepatitis B infection, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.
8. Known or suspected history of drug abuse, as judged by the PI.
9. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or one month after the last visit whichever is the longest. Note: subjects consented and screened, but not randomized in this study or a previous phase I study, are not excluded.
10. Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening.
11. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to AZD7594.
12. Current smokers or those who have smoked or used nicotine products within the 3 months prior to screening.
13. Subjects who are not able to perform correct spirometry tests at screening.
14. Subjects with forced expiratory volume at one second (FEV1) and forced vital capacity (FVC) \<80% predicted (calculated) values and FEV1/FVC ratio \<0.7 in pulmonary function test (spirometry) at Screening Visit.
15. Positive screen for drugs of abuse or cotinine at screening or on each admission to the study center or positive screen for alcohol on each admission to the study center.
16. Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
17. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half-life.
18. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the PI.
19. Involvement of any AstraZeneca, PAREXEL or study site employee or their close relatives.
20. Subjects who have previously received AZD7594.
21. Judgment by the PI that the volunteer should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
22. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes